Metsera raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement. It had offered 17.2 million shares for $15 to $17 each.

Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive data.Maze, a ...

A week after the first IPO of the year was priced, obesity treatment developer Metsera Inc. and renal specialist Maze Therapeutics Inc. have begun trading on Nasdaq. Metsera (NASDAQ:MTSR) surged 47% ...

Metsera (NASDAQ:MTSR) shares opened at $25.50 after being priced at $18 per share, later hitting a high of $28.87. The stock recently sold for $27.75 at around 12:45 p.m. ET. The drug developer pr ...

Metsera's IPO is richest among the Friday debutantes . ... Maze Therapeutics Inc. (MAZE) priced 8.75 million shares at $16 a share for proceeds of $140 million.

Investing.com -- Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its common stock to the public at $18.00 per share, the ...

On the same day as Metsera’s filing, Maze Therapeutics also outlined plans for a $131m Nasdaq IPO, while Ascentage Pharma – already listed in Hong Kong – started trading in the US last week ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. Read our initial report here on Seeking Alpha.

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

Metsera IPO opens 42% higher. View all comments (0) 0. MTSR-2.67%. Investing.com -- Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today.